GlassScriptPhysician profile
Christine E Trotta
NPI 1376956383
$1,431.22
in general payments reported to CMS, 2019-2025
26 companies · $82.86 in 2025
The $82.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2021: $470 · 2022: $32.39 · 2023: $171 · 2024: $424 · 2025: $82.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $201.03 | 2024-2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $134.32 | 2019 | |
| Merck Sharp & Dohme LLC | $126.75 | 2021-2025 | Keytruda, Keytruda Qlex |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Genentech USA, INC. | $116.86 | 2019 | |
| Janssen Biotech, INC. | $98.53 | 2021-2024 | Tecvayli, Talvey |
| Menarini Silicon Biosystems, INC. | $72.01 | 2023-2024 | Cellsearch |
| Ipsen Biopharmaceuticals, INC | $54.98 | 2023 | Tazverik |
| Kite Pharma, INC. | $44.64 | 2024 | Yescarta |
| Celgene Corporation | $41.20 | 2021 | |
| Global Blood Therapeutics, INC. | $39.19 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $37.06 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $32.39 | 2022 | |
| Abbvie INC. | $30.67 | 2021-2024 | |
| Sobi, INC | $30.50 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $29.85 | 2025 | Pyrukynd |
| Pfizer INC. | $29.52 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $24.40 | 2021 | |
| Blueprint Medicines Corporation | $24.11 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.98 | 2021 | |
| Mirati Therapeutics, INC. | $23.12 | 2024 | Krazati |
| Eisai INC. | $22.38 | 2023 | |
| Seagen INC. | $19.51 | 2021 | |
| Array Biopharma INC | $18.50 | 2023 | Lorbrena, Xalkori, Mektovi |
| Jazz Pharmaceuticals INC. | $16.55 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Trotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.